SAN - Sanofi
PAR
->
Healthcare
->
Drug Manufacturers—General
Paris,
France
Type: Equity
SAN price evolution
SAN
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $32926 | $33395 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1797062 | $1816844 | ||
| Current liabilities | ||||
| Accounts payable | ||||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3846 | $4180 | ||
| Long term debt | $308579 | $301268 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1701639 | $1722648 | ||
| Shareholders' equity | ||||
| Retained earnings | $85190 | $82258 | ||
| Other shareholder equity | -$6134 | -$5977 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $175730.3 | |||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | ||||
| Long term investments | ||||
| Property, plant & equipment | $32926 | $33044 | $32342 | $37393.19 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1797062 | $1734659 | $1595835 | $1722874 |
| Current liabilities | ||||
| Accounts payable | ||||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3846 | $3040 | $2187 | $2349 |
| Long term debt | $308579 | $280339 | $246163 | $510512.1 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1701639 | $1645555 | $1508905 | $1618557 |
| Shareholders' equity | ||||
| Retained earnings | $85190 | $76307 | $68397 | -$10019.11 |
| Other shareholder equity | -$6134 | -$5570 | -$4503 | $45097.02 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | ||||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $65408 | $62098 | $54122 | $50579.9 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | ||||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $4276 | $4486 | $4894 | $6433.43 |
| Interest expense | $15703.2 | |||
| Net income | ||||
| Net income | $11076 | $9605 | $8124 | -$10019.11 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2023 | 30 Jul 2022 | 29 Jul 2021 | 30 Apr 2021 |
|---|---|---|---|---|
| Net income | $5349.76 | $2361.77 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $33791.42 | $44514.37 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3898 | -$1652 | -$2021.82 | -$1435.87 |
| Financing activities | ||||
| Dividends paid | -$1848 | -$869 | -$574.74 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$9964 | -$7123 | -$344.6 | -$743.86 |
| Effect of exchange rate | -$1460 | $1976 | $3820.74 | $4787.44 |
| Change in cash and equivalents | $12384 | $587 | $35245.73 | $47122.08 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$8804.85 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $75566.57 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$5366 | -$3898 | -$3715 | -$8247.41 |
| Financing activities | ||||
| Dividends paid | -$2261 | -$1848 | -$1313 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$172 | -$9973 | $777 | -$2180.65 |
| Effect of exchange rate | -$322 | -$1460 | $5196 | -$4857.06 |
| Change in cash and equivalents | -$845 | $12375 | $58949 | $60281.46 |
News
|
France shares higher at close of trade; CAC 40 up 0.58% By Investing.com
Investing.com
22 Nov 2024
|
|
Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?
Investor's Business Daily
21 Nov 2024
|
|
Here’s What Drove Sanofi’s (SNY) Earnings
Insider Monkey · via Yahoo Finance
20 Nov 2024
|
|
Is BioNTech SE (BNTX) the Best German Stock to Buy Now?
Insider Monkey · via Yahoo Finance
20 Nov 2024
|
|
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right...
Insider Monkey · via Yahoo Finance
20 Nov 2024
|
|
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Zacks · via Yahoo Finance
18 Nov 2024
|
|
Health Stocks Slide as Trump Picks Vaccine Skeptic Kennedy
Bloomberg
15 Nov 2024
|
|
European Stocks Fall as Traders Trim Rate-Cut Bets; Sanofi Drops
Bloomberg
15 Nov 2024
|
|
European stocks slip slightly; UK economy contracted in September By...
Investing.com
15 Nov 2024
|
|
Europe’s STOXX 600 opens lower as tech, healthcare shares drag
KFGO
15 Nov 2024
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |